In STAT's AACR Recap, reporters Matthew Herper and Angus Chen discussed the mood and highlights of one of the world's largest ...

Stories of personal connection to their work weren’t uncommon at the UB RENEW Institute’s spring poster session and ...

Starting in 2025, the Eylea franchise as a whole began to decline due to competitive pressure from long-acting Vabysmo, which competes with Eylea HD, and Pabvlu, a biosimilar version of the original ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported ...

Explore Regeneron's Q1 2025 earnings with updates on Dupixent growth, EYLEA challenges, FDA hurdles, and upcoming approvals.

--Down 11.5% month-to-date; on pace for worst month since Oct. 2024, when it fell 20.27% --Down 53.29% from its all-time closing high of $1201.76 on Aug. 27, 2024 --Down 36.98% from 52 weeks ago ...

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced ...

BioNTech SE(Nasdaq: BNTX, "BioNTech" or "the Company") will present data for selected assets from its diversified oncology ...

Regeneron Pharmaceuticals has entered a new manufacturing and supply agreement with Fujifilm Diosynth Biotechnologies to ...

the research working group included students Sophia Carlson, Emma Crandell, Marquel Gardner, Michelle Martinez and Sofia Perez. The students designed a series of five protest posters, each ...